Tenet Healthcare Corporation
THCBusiness Overview
source: coverage-next-full ticker: THC step: "01" title: Business Overview — Segments, Operations, Strategic Pivot created: 2026-05-29
THC — Business Overview
Company Summary
Tenet Healthcare Corporation is one of the largest investor-owned healthcare services companies in the United States. Founded in 1967 (as National Medical Enterprises), Tenet today operates a dual-track business: a legacy portfolio of acute-care hospitals concentrated in high-growth Sun Belt markets, and a fast-growing ambulatory surgery center (ASC) platform — United Surgical Partners International (USPI) — that is becoming the company's primary earnings engine.
Headquartered in Dallas, Texas, Tenet serves millions of patients annually through hospitals, surgical facilities, emergency departments, imaging centers, and ancillary outpatient services. The company employs approximately 110,000 people across more than 30 states.
Strategic Context: The Hospital-to-ASC Transformation
Under CEO Saum Sutaria (appointed 2021), Tenet has been executing a deliberate strategic pivot away from low-margin, capital-intensive acute-care hospitals toward high-margin, asset-light ambulatory surgery centers. The thesis: ASCs generate EBITDA margins of 35–40% at the facility level vs. 12–15% for hospitals, require less capex, carry lower reimbursement risk, and benefit from secular tailwinds as payers and patients push surgical volumes out of hospital settings.
The execution playbook:
- Divest non-strategic hospitals (especially smaller community hospitals with challenged demographics)
- Reinvest proceeds into USPI ASC acquisitions and de novo builds
- Buy back shares aggressively to offset dilution and return capital
- Deleverage the balance sheet over time via free cash flow
Business Segments
1. Hospital Operations and Other (~65% of revenue)
- Scale: Approximately 55 acute-care hospitals with ~15,000 licensed beds (as of FY 2024, down from ~65 five years ago via divestitures)
- Geography: Concentrated in Texas, Florida, Michigan, California, and other Sun Belt/high-growth states
- Mix: Primarily general acute-care hospitals; some specialty hospitals; affiliated outpatient facilities
- Payer mix: Managed care (~50%), Medicare (~25%), Medicaid (~15%), self-pay/uninsured (~7%), other (~3%)
- Key metrics: Admissions, same-hospital revenue growth, adjusted admissions, net revenue per adjusted admission, EBITDA margin (~12–15%)
- Conifer Health Solutions: A revenue cycle management (RCM) subsidiary in which Tenet holds ~76%; provides billing/coding/collections for Tenet and third-party hospital clients. Results consolidated within Hospital segment.
2. Ambulatory Care — USPI (~35% of revenue, ~45%+ of EBITDA)
- Scale: >500 ambulatory surgery centers and surgical hospitals (as of FY 2024), operating across 36 states
- Structure: USPI operates as a joint venture platform — Tenet owns ~80% of USPI, with physician and health system co-investors owning the remainder. Individual ASC facilities are themselves JVs (Tenet/USPI typically owns 51–70%, physicians own the rest)
- Specialties: Orthopedics (joint replacement, spine), ophthalmology, general surgery, gastroenterology, pain management, cardiac (growing)
- Business model: Facility fee revenue from surgical procedures; no employed physicians (physicians are partners/owners, not employees)
- Revenue drivers: Case volume growth, reimbursement rates, payer mix improvement (commercial vs. Medicare), new service line additions (total joint replacement shift from inpatient to outpatient)
- Key metrics: Cases performed, revenue per case, EBITDA margin (~35–40% at facility level), new facilities added per year, same-facility growth
- Competition: Surgery Partners (SGRY), AmSurg (private, owned by Envision/KKR), SCA Health (Optum/UnitedHealth), independent physician-owned ASCs
Ownership / Corporate Structure Highlights
- Publicly traded on NYSE (THC); market cap ~$12–14B (as of early 2025)
- Tenet consolidates USPI (~80% ownership) with non-controlling interest (~20%)
- Conifer Health consolidated (~76% ownership) within Hospital segment
- Significant leveraged balance sheet (~$15B long-term debt); deleveraging is a key management priority
Customers / Patients
Tenet's "customers" are patients, but the economic payers are:
- Commercial insurance (largest contributor to revenue and margins)
- Medicare (largest by volume; increasingly important for outpatient as CMS expands the ASC-covered procedures list)
- Medicaid (lower reimbursement; varies by state)
- Self-pay/charity care (cost to provide; partially offset by government funding)
Why Tenet is Interesting
- Re-rating story: As USPI grows to represent a larger share of earnings, Tenet's blended multiple should expand toward ASC peer multiples (Surgery Partners, Addus HomeCare) from depressed hospital multiples
- Execution proof: Management has consistently hit divestiture targets and USPI growth targets
- Deleveraging path: Free cash flow + divestiture proceeds create a credible path to sub-4x leverage by 2026
- Buybacks: Aggressive share repurchase in a leveraged capital structure magnifies EPS growth
- Site-of-care tailwind: CMS annually adds procedures to the ASC-approved list; total hip/knee replacement now approved — enormous volume opportunity
Financial Snapshot
source: coverage-next-full ticker: THC step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
THC — Financial Snapshot
Consolidated Income Statement Summary
| Metric (in millions) | FY 2022 | FY 2023 | FY 2024E |
|---|---|---|---|
| Net Revenue | $19,182 | $20,310 | ~$20,700 |
| Revenue Growth YoY | +5.1% | +5.9% | ~+2% |
| Cost of Services (excl. D&A) | ~$16,100 | ~$16,800 | ~$17,100 |
| Gross Profit | ~$3,082 | ~$3,510 | ~$3,600 |
| Gross Margin | ~16.1% | ~17.3% | ~17.4% |
| SG&A / Other Operating | ~$900 | ~$950 | ~$970 |
| Adjusted EBITDA | ~$2,900 | ~$3,300 | ~$3,500 |
| Adjusted EBITDA Margin | ~15.1% | ~16.3% | ~16.9% |
| Depreciation & Amortization | ~$900 | ~$900 | ~$880 |
| Adjusted EBIT | ~$2,000 | ~$2,400 | ~$2,620 |
| Interest Expense | ~$770 | ~$740 | ~$700 |
| Other / Non-recurring | $(200) | $(100) | $(50) |
| Pre-tax Income (Adjusted) | ~$1,030 | ~$1,560 | ~$1,870 |
| Income Tax Expense | ~$270 | ~$390 | ~$465 |
| Effective Tax Rate | ~26% | ~25% | ~25% |
| Net Income (Adjusted) | ~$760 | ~$1,170 | ~$1,405 |
| Non-controlling Interests | ~$(270) | ~$(320) | ~$(370) |
| Net Income Attr. to THC | ~$490 | ~$850 | ~$1,035 |
| Adjusted EPS (Diluted) | ~$4.80 | ~$8.50 | ~$10.50 |
| Diluted Shares (M) | ~102 | ~100 | ~99 |
Note: Figures blend reported results and management-adjusted metrics. FY 2024E = estimates based on guidance and quarterly trajectory. GAAP results include non-cash impairments, restructuring charges, and gains/losses on divestitures that are excluded from adjusted figures.
GAAP vs. Adjusted Reconciliation (Key Items)
| Item | FY 2022 | FY 2023 |
|---|---|---|
| Reported GAAP Net Income (Loss) | ~$(273)M | ~$611M |
| +Impairment charges | ~$430M | ~$80M |
| +Restructuring/transaction costs | ~$80M | ~$70M |
| +/(−) Gains on divestitures | ~$(70)M | ~$(50)M |
| +Stock-based compensation | ~$85M | ~$90M |
| Adjusted Net Income | ~$490M | ~$850M |
Note: FY 2022 GAAP net loss largely driven by goodwill impairment charges on certain hospital market groups.
Segment EBITDA Breakdown
| Segment | FY 2022 EBITDA | FY 2022 Margin | FY 2023 EBITDA | FY 2023 Margin |
|---|---|---|---|---|
| Hospital Operations | ~$1,750M | ~14% | ~$1,900M | ~14.5% |
| Ambulatory Care (USPI) | ~$1,050M | ~32% | ~$1,300M | ~34% |
| Corporate/Eliminations | ~$(350)M | — | ~$(350)M | — |
| Consolidated Adj. EBITDA | ~$2,900M | ~15.1% | ~$3,300M | ~16.3% |
Key insight: USPI (~35% of revenues) generates ~40% of EBITDA and its margin (~34–38%) is 2x+ the Hospital segment margin (~14%). As USPI grows, blended margins expand — the core re-rating thesis.
Earnings Per Share Trajectory
| Year | Adj. EPS | YoY Growth | GAAP EPS |
|---|---|---|---|
| FY 2020 | ~$2.50 | N/M (COVID) | ~$(7.50) |
| FY 2021 | ~$5.20 | +108% | ~$3.80 |
| FY 2022 | ~$4.80 | −8% | ~$(2.70) |
| FY 2023 | ~$8.50 | +77% | ~$5.60 |
| FY 2024E | ~$10.50 | +24% | ~$8.00 |
Notes on volatility:
- FY 2022 EPS decline: higher interest expense, elevated labor costs, normalization of COVID-era benefits
- FY 2023 surge: margin recovery + USPI growth + buybacks; surgical volumes recovered strongly
- FY 2024E: Continued USPI growth + operational leverage + reduced share count
Key Profitability Metrics
| Metric | FY 2022 | FY 2023 | FY 2024E |
|---|---|---|---|
| Gross Margin | 16.1% | 17.3% | 17.4% |
| Adjusted EBITDA Margin | 15.1% | 16.3% | 16.9% |
| Adjusted EBIT Margin | ~10.4% | ~11.8% | ~12.7% |
| Adjusted Net Margin | ~4.1% | ~5.8% | ~6.8% |
| Interest Coverage (EBITDA/Int.) | ~3.8x | ~4.5x | ~5.0x |
Cash Flow Summary
| Metric (in millions) | FY 2022 | FY 2023 |
|---|---|---|
| Operating Cash Flow | ~$1,500 | ~$1,800 |
| Capex | ~$(800) | ~$(800) |
| Free Cash Flow | ~$700 | ~$1,000 |
| Divestiture Proceeds | ~$500 | ~$200 |
| Share Repurchases | ~$(500) | ~$(600) |
| Debt Repayment (net) | ~$(200) | ~$(300) |
Free cash flow generation is strong and growing, supporting both deleveraging and buybacks. FCF conversion (FCF/Adjusted Net Income) is approximately 90–100%.
Quality of Earnings Assessment
- Revenue quality: High — primarily patient service revenue under multi-year managed care contracts
- Earnings persistence: USPI EBITDA highly visible; hospital EBITDA more volatile (labor, payer mix)
- Non-recurring charges: Frequent impairment and restructuring charges make GAAP earnings less meaningful; adjusted metrics are appropriate
- Working capital: Hospitals have high DSO (~55–65 days) but predictable; ASCs have much faster collections (~30 days)
- Cash conversion: Strong; minimal working capital build given service business
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $THC.